Gluten-free diet can ameliorate the symptoms of non-celiac autoimmune diseases.

autoimmune disease gluten withdrawal gluten-free diet gut –peripheral organs axes gut–brain axes microbiome/dysbiome ratio non-celiac autoimmune disease

Journal

Nutrition reviews
ISSN: 1753-4887
Titre abrégé: Nutr Rev
Pays: United States
ID NLM: 0376405

Informations de publication

Date de publication:
10 02 2022
Historique:
received: 19 11 2020
revised: 05 04 2021
accepted: 12 05 2021
pubmed: 3 8 2021
medline: 31 3 2022
entrez: 2 8 2021
Statut: ppublish

Résumé

A gluten-free diet (GFD) is the recommended treatment for gluten-dependent disease. In addition, gluten withdrawal is popular and occasionally is suggested as a treatment for other autoimmune diseases (ADs). The current systematic review summarizes those entities and discusses the logic behind using a GFD in classical non-gluten-dependentADs. A search for medical articles in PubMed/MEDLINE, Web of Sciences, LILACS, and Scielo published between 1960 and 2020 was conducted, using the key words for various ADs and GFDs. Eight-three articles were included in the systematic review (using PRISMA guidelines). Reduction in symptoms of ADs after observance of a GFD was observed in 911 out of 1408 patients (64.7%) and in 66 out of the 83 selected studies (79.5%). The age of the patients ranged from 9 months to 69 years. The duration of the GFD varied from 1 month to 9 years. A GFD can suppress several harmful intraluminal intestinal events. Potential mechanisms and pathways for the action of GFD in the gut - remote organs' axis have been suggested. A GFD might represent a novel nutritional therapeutic strategy for classical non-gluten-dependent autoimmune conditions.

Identifiants

pubmed: 34338776
pii: 6335547
doi: 10.1093/nutrit/nuab039
doi:

Substances chimiques

Glutens 8002-80-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

525-543

Informations de copyright

© The Author(s) 2021. Published by Oxford University Press on behalf of the International Life Sciences Institute. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Aaron Lerner (A)

The Zabludowicz Research Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel.

Jozélio Freire de Carvalho (J)

Department of Rheumatology, Institute for Health Sciences of the Federal University of Bahia, Salvador, Bahia, Brazil.

Anna Kotrova (A)

Department of Autoimmune research, Saint Petersburg State University, St. Petersburg, Russia.

Yehuda Shoenfeld (Y)

The Zabludowicz Research Center for Autoimmune Diseases, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Department of Autoimmune research, Saint Petersburg State University, St. Petersburg, Russia.
Department of Administration, Ariel University, Israel.
Department of Autoimmune research, I.M Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH